| __timestamp | Amicus Therapeutics, Inc. | Galapagos NV |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 111110000 |
| Thursday, January 1, 2015 | 76943000 | 129714000 |
| Friday, January 1, 2016 | 104793000 | 139574000 |
| Sunday, January 1, 2017 | 149310000 | 218502000 |
| Monday, January 1, 2018 | 270902000 | 322876000 |
| Tuesday, January 1, 2019 | 286378000 | 427320000 |
| Wednesday, January 1, 2020 | 308443000 | 523667000 |
| Friday, January 1, 2021 | 272049000 | 491707000 |
| Saturday, January 1, 2022 | 276677000 | 515083000 |
| Sunday, January 1, 2023 | 152381000 | 241294000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Amicus Therapeutics and Galapagos NV have been at the forefront of this race. From 2014 to 2023, Galapagos NV consistently outpaced Amicus Therapeutics in R&D investment, with an average annual expenditure approximately 60% higher. Notably, in 2020, Galapagos NV's R&D spending peaked at over 5.2 times its 2014 level, reflecting a robust commitment to innovation. Meanwhile, Amicus Therapeutics saw a significant increase in R&D spending, peaking in 2020 before a notable decline in 2023. This trend suggests a strategic shift or potential challenges in their pipeline. As the biotech industry evolves, these spending patterns offer insights into each company's strategic priorities and potential future breakthroughs.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Galapagos NV
Research and Development Investment: Pharming Group N.V. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and Galapagos NV
Analyzing R&D Budgets: Verona Pharma plc vs Galapagos NV
Research and Development Expenses Breakdown: ADMA Biologics, Inc. vs Amicus Therapeutics, Inc.
Analyzing R&D Budgets: Amneal Pharmaceuticals, Inc. vs Galapagos NV
Comparing Innovation Spending: Apellis Pharmaceuticals, Inc. and Galapagos NV
CRISPR Therapeutics AG vs Galapagos NV: Strategic Focus on R&D Spending
R&D Spending Showdown: ACADIA Pharmaceuticals Inc. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Research and Development Investment: Amicus Therapeutics, Inc. vs Viridian Therapeutics, Inc.